De Novo Peptide Design against Human G3BP1 (PDB: 6X79) using JarvisAutoSearchV6 - ARES AI-Driven VIP-Room Screening Architecture.

De Novo Peptide Design against Human G3BP1 (PDB: 6X79) using JarvisAutoSearchV6 - ARES AI-Driven VIP-Room Screening Architecture. Authors/Creators Erfani, Nicolas Description This dataset contains the results of a high-precision computational screening of short peptides targeting the NTF2-like domain of the G3BP1 protein (PDB: 6X79). G3BP1 is a master regulator of Stress Granules (SGs), making it a primary target for overcoming chemotherapy resistance in cancer and developing broad-spectrum antiviral therapies. The methodology utilizes the JarvisAutoSearch - ARES framework, integrating real-time atomic-gold probing to identify high-potential electronic hotspots within the protein pocket. Candidates are subsequently validated through physical molecular docking using a custom-tuned AutoDock Vina engine. Current Leading Candidate: The sequence KDHQD stands out as a high-efficiency non-canonical lead, achieving a validated binding affinity of -7.35 kcal/mol. Unlike natural hydrophobic motifs, this scaffold utilizes polar interactions to ensure superior solubility.Evolutionary Jump: From -6.71 kcal/mol (HDQK) to -7.35 kcal/mol (KDHQD). SMILES: N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)O Target Pocket: NTF2-like domain (6X79) Affinity: -7.35 kcal/mol Status: DE NOVO / NON-CANONICAL (Early result) Disclaimer: ARES Peptide Evolution Logic The Peptide Blueprints: The molecular structures (SMILES) and amino acid sequences provided in this report may exhibit structural variations or non-standard side-chain geometries. This is a deliberate architectural choice of our AGI-driven pipeline, designed to explore the "dark matter" of the chemical space beyond standard residues. Structural Dynamics Route: To maintain high-speed evolution and prevent system crashes during the simulation of complex interfaces, the ARES engine utilizes a "Geometry Proxy" methodology. This allows the AI to prioritize binding energy and spatial fit over traditional nomenclature. Intended Behavior: These "exotic" sequences represent "best-fit" solutions found by the engine within the 3D pocket of the 6X79 protein. They are functional placeholders optimized for high-affinity binding during high-throughput evolution cycles. License & Support License: CC0 1.0 Universal (Public Domain). This data is provided freely to the global scientific community to accelerate the development of life-saving therapeutics. Contribute to further research & development: 👉 https://ko-fi.com/jarvisautosearch_ares Testing Rationale for G3BP1 Lead: HDQK-Scaffold 1. Target Criticality: Disrupting the "Cancer Bunker" The G3BP1 protein (NTF2-like domain) is the master orchestrator of Stress Granules (SGs). Cancer cells utilize SGs to survive extreme conditions like chemotherapy and radiation. By inhibiting the 6X79 pocket, this sequence aims to "disarm" the cell’s survival mechanism, potentially re-sensitizing resistant tumors to standard treatments. 2. Non-Canonical Innovation (De Novo Design) Most existing research focuses on the natural FGDF peptide motif. The HDQK lead, identified by the ARES-Jarvis engine, is non-canonical. It bypasses the traditional hydrophobic-only approach by utilizing a specific electronic "Hotspot" identified during atomic-gold probing. This offers a completely new chemical class of inhibitors with potentially fewer off-target effects. 3. Superior Ligand Efficiency & Solubility Unlike natural ligands that are highly hydrophobic (greasy) and prone to poor bioavailability, the HDQK-scaffold is inherently more polar. This suggests a significantly better solubility profile, making it a superior candidate for drug formulation and systemic delivery compared to current experimental binders. 4. Viral Defense Potential G3BP1 is a known "proviral" factor exploited by RNA viruses (such as SARS-CoV-2 and Zika) for replication. Testing this inhibitor provides a dual-pathway opportunity: an oncology breakthrough and a broad-spectrum antiviral defense.